Floatz logo

N-(5-ISOQUINOLINESULFONYL)-1,4-PERHYDRODIAZEPINE

Idiopathic Parkinson´s Disease

Technical University of MunichSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

255 Active assets in the Idiopathic Parkinson´s Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Istradefylline
Georgetown University
Phase 4BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Pardoprunox
Abbott Products
Phase 3BBB

View all 50 →

Same molecule, other indications

N-(5-ISOQUINOLINESULFONYL)-1,4-PERHYDRODIAZEPINE is also rated in:

prostate cancerDormant
B
Indicative ·
62 / 100
View asset →
amyotrophic lateral sclerosisDormant
CCC
Indicative ·
54 / 100
View asset →
cognitive disorderDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →